Based on the pre-clinical studies and ASCEND-1 data, ceritinib received an accelerated approval from FDA for the treatment of ALK-positive metastatic NSCLC patients with disease progression or intolerance to crizotinib. Here, ALK is linked to non-small cell lung carcinoma.